✦ LIBER ✦

Equations for bolus intravenous injection in linear pharmacokinetics

✍ Scribed by John G. Wagner

Publisher: John Wiley and Sons
Year: 1976
Tongue: English
Weight: 97 KB
Volume: 65
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.2600650846

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of melatonin in man aft

Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection

✍ C. Mallo; R. Zaidan; G. Galy; E. Vermeulen; J. Brun; G. Chazot; B. Claustrat 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 490 KB

The pharmacokinetics of melatonin during the day-time has been studied in 4 healthy subjects after a bolus i.v. injection of 5 or 10 micrograms/person and after a 5 h infusion of 20 micrograms per person in 6 healthy subjects. In addition, a pinealomectomized patient whose nocturnal plasma melatonin

Comparative pharmacokinetics of sisomici

Comparative pharmacokinetics of sisomicin after intravenous injection, intravenous infusion and intramuscular injection in man

✍ V. Bonomini; A. Albertazzi 📂 Article 📅 1976 🏛 Springer-Verlag 🌐 English ⚖ 466 KB

Expression of intravenous-infusion equat

Expression of intravenous-infusion equations in terms of coefficients and exponents of bolus intravenous equations

✍ Nelson L. Lui; Thorir D. Bjornsson 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

Pharmacokinetics of bolus intravenous an

Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects

✍ P. Harper; C. -E. Elwin; G. Cederblad 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 621 KB

Pharmacokinetics of intravenous and oral

Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects

✍ P. Harper; C. -E. Elwin; G. Cederblad 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 712 KB

Administration of the bisphosphonate iba

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

✍ Martin Pecherstorfer; Heinz Ludwig; Karl Schlosser; Signe Buck; Hermann-Josef Hu 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 615 KB

## Abstract Bisphosphonates (BPs) are used for the treatment of both benign and malignant diseases characterized by increased bone resorption. Because of their potential nephrotoxicity, currently available BPs have to be administered by slow intravenous infusion, with conventional doses requiring a